Sign up for the premium plan and unlock all options
After purchasing the premium plan, you will unlock all information about drug prices and their availability.
Search
Listing 25921 - 25940 out of 505060 entries
| Country | ATC | Drug name | Drug form, strength, package | Price level | Price in € | Price in local currency | Therapeutic areas | Manufacturer / Importer |
|---|---|---|---|---|---|---|---|---|
| Australia | (S01LA04) ranibizumab | Lucentis 2.3 mg/0.23 mL injection, 0.23 mL vial | Solution for intravitreal injection 2.3 mg in 0.23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (S01LA04) ranibizumab | Lucentis 2.3 mg/0.23 mL injection, 0.23 mL vial | Solution for intravitreal injection 2.3 mg in 0.23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (S01LA04) ranibizumab | Lucentis 2.3 mg/0.23 mL injection, 0.23 mL vial | Solution for intravitreal injection 2.3 mg in 0.23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (S01LA05) aflibercept | Eylea 8 mg/0.07 mL injection, 0.07 mL vial | Solution for intravitreal injection 11.43 mg in 100 microlitres (114.3 mg per mL), 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | BayerAustraliaLtd |
| Australia | (S01LA05) aflibercept | Eylea 8 mg/0.07 mL injection, 0.07 mL vial | Solution for intravitreal injection 11.43 mg in 100 microlitres (114.3 mg per mL), 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | BayerAustraliaLtd |
| Australia | (S01LA05) aflibercept | Eylea 8 mg/0.07 mL injection, 0.07 mL vial | Solution for intravitreal injection 11.43 mg in 100 microlitres (114.3 mg per mL), 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | BayerAustraliaLtd |
| Australia | (S01LA05) aflibercept | Eylea 8 mg/0.07 mL injection, 0.07 mL vial | Solution for intravitreal injection 11.43 mg in 100 microlitres (114.3 mg per mL), 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | BayerAustraliaLtd |
| Australia | (S01LA05) aflibercept | Eylea 2 mg/0.05 mL injection, 0.05 mL syringe | Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | BayerAustraliaLtd |
| Australia | (S01LA05) aflibercept | Eylea 2 mg/0.05 mL injection, 0.05 mL syringe | Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | BayerAustraliaLtd |
| Australia | (S01LA05) aflibercept | Eylea 2 mg/0.05 mL injection, 0.05 mL syringe | Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | BayerAustraliaLtd |
| Australia | (S01LA05) aflibercept | Eylea 2 mg/0.05 mL injection, 0.05 mL syringe | Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | BayerAustraliaLtd |
| Australia | (S01LA05) aflibercept | Eylea 2 mg/0.05 mL injection, 0.05 mL syringe | Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | BayerAustraliaLtd |
| Australia | (S01LA05) aflibercept | Eylea 2 mg/0.05 mL injection, 0.05 mL syringe | Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | BayerAustraliaLtd |
| Australia | (S01LA05) aflibercept | Eylea 2 mg/0.05 mL injection, 0.05 mL syringe | Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | BayerAustraliaLtd |
| Australia | (S01LA05) aflibercept | Eylea 2 mg/0.05 mL injection, 0.05 mL syringe | Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | BayerAustraliaLtd |
| Australia | (S01LA05) aflibercept | Eylea 2 mg/0.05 mL injection, 0.05 mL vial | Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL), 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | BayerAustraliaLtd |
| Australia | (S01LA05) aflibercept | Eylea 2 mg/0.05 mL injection, 0.05 mL vial | Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL), 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | BayerAustraliaLtd |
| Australia | (S01LA05) aflibercept | Eylea 2 mg/0.05 mL injection, 0.05 mL vial | Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL), 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | BayerAustraliaLtd |
| Australia | (S01LA05) aflibercept | Eylea 2 mg/0.05 mL injection, 0.05 mL vial | Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL), 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | BayerAustraliaLtd |
| Australia | (S01LA05) aflibercept | Eylea 2 mg/0.05 mL injection, 0.05 mL vial | Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL), 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | BayerAustraliaLtd |
